Sicelo Masangwana shuts his office door in Somkele, a settlement of approximately 6,000 residents near Mtubatuba in northern KwaZulu-Natal. He strides toward the building's foyer where a group of twenty-somethings eagerly await him, wiping his forehead and taking a deep breath.
"This is going to be a lengthy day," he remarks with a smile.
Outside, children play barefoot football on the dusty street leading into the village from the paved highway. Occasionally, residents come and go from their homes, carrying out their daily tasks as usual by mid-morning on weekdays.
It's a typical Tuesday in March, around 10:30 am. In the Mtubatuba municipality, located roughly 50 km north of Richards Bay, approximately 1% of the population is afflicted with tuberculosis (TB). Symptoms of TB typically include weight loss, night sweats, persistent fever, or an ongoing cough.
TB rates in this area are elevated, in part due to the high prevalence of HIV infection, with about three out of ten individuals contracting the virus. (HIV-positive individuals are up to 20 times more susceptible to TB compared to those without HIV.)
Masangwana, a researcher at the Africa Health Research Institute (AHRI), is overseeing a clinical trial here as part of a broader study assessing the efficacy of a potential new TB vaccine called M72/AS01E.
A previous phase two trial demonstrated that the vaccine could protect at least half of those infected with TB from falling ill and was deemed safe. This promising outcome led to the initiation of a larger phase three trial, which Masangwana is now focusing on.
This endeavor, spanning seven countries and involving 60 sites and 20,000 participants aged 15 to 44, aims to evaluate the vaccine's effectiveness. In South Africa, the AHRI site aims to enroll approximately 1,000 participants by year-end.
The trial involves administering two doses of the vaccine one month apart to half of the participants, while the other half receives placebos. The outcomes will determine the vaccine's ability to prevent illness.
Currently, the only TB vaccine available is the Calmette-Guérin (BCG) vaccine, administered to infants at birth. However, its protection wanes by adulthood, rendering it ineffective if administered later in life.
In 2022, over nine million adults worldwide fell ill with TB, underscoring the urgent need for a vaccine to prevent transmission. M72 offers a promising opportunity to combat the disease, which claimed 1.3 million lives globally in 2022, twice the number of deaths attributed to HIV.
Researchers anticipate final trial results within the next four to five years.
As they roll out the trial, researchers in rural South Africa consider several key factors:
1. Gradual Onset and Scaling: The trial begins gradually, with the aim of enrolling 100 participants by the end of April before scaling up operations to meet year-end targets.
2. Community Engagement: Researchers target areas with high TB prevalence, engaging community members through various channels, including outreach at taxi ranks, sports stadiums, shops, and other community hubs.
3. Participant Support: Participants receive transportation to and from the research site, regular health check-ups, and compensation for their time and expenses, ensuring sustained involvement throughout the trial period.
4. Understanding Community Dynamics: Researchers navigate challenges such as crime and cultural norms to ensure smooth trial implementation. Understanding community dynamics helps anticipate and address potential obstacles to participation.
Despite challenges, researchers remain committed to advancing TB vaccine research, with the potential for South Africa to lead global efforts in TB prevention—a significant milestone in public health.
"This is going to be a lengthy day," he remarks with a smile.
Outside, children play barefoot football on the dusty street leading into the village from the paved highway. Occasionally, residents come and go from their homes, carrying out their daily tasks as usual by mid-morning on weekdays.
It's a typical Tuesday in March, around 10:30 am. In the Mtubatuba municipality, located roughly 50 km north of Richards Bay, approximately 1% of the population is afflicted with tuberculosis (TB). Symptoms of TB typically include weight loss, night sweats, persistent fever, or an ongoing cough.
TB rates in this area are elevated, in part due to the high prevalence of HIV infection, with about three out of ten individuals contracting the virus. (HIV-positive individuals are up to 20 times more susceptible to TB compared to those without HIV.)
Masangwana, a researcher at the Africa Health Research Institute (AHRI), is overseeing a clinical trial here as part of a broader study assessing the efficacy of a potential new TB vaccine called M72/AS01E.
A previous phase two trial demonstrated that the vaccine could protect at least half of those infected with TB from falling ill and was deemed safe. This promising outcome led to the initiation of a larger phase three trial, which Masangwana is now focusing on.
This endeavor, spanning seven countries and involving 60 sites and 20,000 participants aged 15 to 44, aims to evaluate the vaccine's effectiveness. In South Africa, the AHRI site aims to enroll approximately 1,000 participants by year-end.
The trial involves administering two doses of the vaccine one month apart to half of the participants, while the other half receives placebos. The outcomes will determine the vaccine's ability to prevent illness.
Currently, the only TB vaccine available is the Calmette-Guérin (BCG) vaccine, administered to infants at birth. However, its protection wanes by adulthood, rendering it ineffective if administered later in life.
In 2022, over nine million adults worldwide fell ill with TB, underscoring the urgent need for a vaccine to prevent transmission. M72 offers a promising opportunity to combat the disease, which claimed 1.3 million lives globally in 2022, twice the number of deaths attributed to HIV.
Researchers anticipate final trial results within the next four to five years.
As they roll out the trial, researchers in rural South Africa consider several key factors:
1. Gradual Onset and Scaling: The trial begins gradually, with the aim of enrolling 100 participants by the end of April before scaling up operations to meet year-end targets.
2. Community Engagement: Researchers target areas with high TB prevalence, engaging community members through various channels, including outreach at taxi ranks, sports stadiums, shops, and other community hubs.
3. Participant Support: Participants receive transportation to and from the research site, regular health check-ups, and compensation for their time and expenses, ensuring sustained involvement throughout the trial period.
4. Understanding Community Dynamics: Researchers navigate challenges such as crime and cultural norms to ensure smooth trial implementation. Understanding community dynamics helps anticipate and address potential obstacles to participation.
Despite challenges, researchers remain committed to advancing TB vaccine research, with the potential for South Africa to lead global efforts in TB prevention—a significant milestone in public health.
About this article
From the Medical Directory library. For advice about your own health, speak to your healthcare professional.
JOIN THE CONVERSATION
No comments yet. Add a thoughtful question or comment about this article.